Skip to Main content Skip to Navigation

Coût de l’antibiorésistance en France : évaluation à partir des bases de données médico-administratives

Abstract : Antimicrobial resistance (AMR) is a major threat to global public health, makes infections more difficult to treat, and potentially jeopardizes medical progress and innovation. AMR is also associated with higher morbidity and mortality. Assessing the economic burden of AMR could highlight priorities in prevention, research and management for decision-makers. The main objective of this Ph.D. dissertation is to assess the economic impact of AMR in France based on data from the National Health Data System (SNDS) database. SNDS contains patient-level medical data and inpatient and outpatient care costs reimbursed by national health insurance. We thus used SNDS to analyse care pathways and associated costs among a population that included all hospitalized patients with acute bacterial infection (classified into 13 infectious sites). First, we investigated the hospital cost from the payer's perspective. Through a matched case-control design, we estimated an additional hospital cost of €110 million caused by AMR in 2015, with an extrapolation showing that the overall cost could reach €290 million. Second, we focused on the effects at 12 months of hospitalization with AMR. In this context, four studies were developed. (1) For patients with resistant infections, a sequence analysis identified five distinct hospital pathways. Longest hospital stays were observed for bone and joint infections, whereas patients with heart and mediastinum infections or lower respiratory tract infections had higher mortality rates. (2) Ambulatory expenditure was studied using a difference-in-difference approach and we showed a low overconsumption due to AMR, limited to the first month following hospitalization. (3) Hospital resource consumption measured by duration of hospitalization due to AMR was increased in acute care hospital stays for infection and in hospitalization at home. (4) Additional hospital cost due to antibiotic resistance during the year following initial hospitalization was estimated at €618 [IC95% 419; 817] per patient. In conclusion, using five economic criteria this Ph.D dissertation has shown that AMR bears a substantial cost burden on the French public health insurance system.
Complete list of metadatas

Cited literature [236 references]  Display  Hide  Download
Contributor : Abes Star :  Contact
Submitted on : Friday, July 10, 2020 - 4:44:18 PM
Last modification on : Wednesday, October 14, 2020 - 4:06:51 AM


Version validated by the jury (STAR)


  • HAL Id : tel-02896665, version 1



Mehdi Benjamin Touat. Coût de l’antibiorésistance en France : évaluation à partir des bases de données médico-administratives. Maladies infectieuses. Université Paris-Saclay, 2020. Français. ⟨NNT : 2020UPASV005⟩. ⟨tel-02896665⟩



Record views


Files downloads